TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA
Clinical trials for TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cocktail targets tough lymphoma cancers
Disease control OngoingThis early-phase study tests a combination of three drugs (obinutuzumab, venetoclax, and lenalidomide) in 22 adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goal is to find the safest dose and see if the combination can shri…
Matched conditions: TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New drug combo shows promise for tough lymphoma
Disease control OngoingThis study tests adding an experimental drug called selinexor to the standard chemotherapy R-CHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than standard treatment alone. About 43 adults with advanced …
Matched conditions: TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Supercharged immune cells take on tough lymphoma after transplant
Disease control OngoingThis early-phase trial tests a new approach for people with aggressive B-cell non-Hodgkin lymphoma that has come back after treatment. After a standard stem cell transplant, patients receive their own immune cells (T cells) that have been genetically modified in a lab to better r…
Matched conditions: TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 08, 2026 12:01 UTC